Sei Investments Co. Sells 3,701 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Sei Investments Co. lowered its position in United Therapeutics Co. (NASDAQ:UTHR) by 6.6% during the 4th quarter, Holdings Channel reports. The firm owned 52,097 shares of the biotechnology company’s stock after selling 3,701 shares during the quarter. Sei Investments Co.’s holdings in United Therapeutics were worth $18,383,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of UTHR. Newbridge Financial Services Group Inc. bought a new position in shares of United Therapeutics during the 4th quarter worth $25,000. Brooklyn Investment Group purchased a new stake in United Therapeutics in the third quarter worth about $33,000. Millstone Evans Group LLC bought a new position in United Therapeutics during the 4th quarter worth about $67,000. MassMutual Private Wealth & Trust FSB grew its holdings in United Therapeutics by 31.9% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock worth $85,000 after acquiring an additional 58 shares in the last quarter. Finally, Jones Financial Companies Lllp raised its holdings in shares of United Therapeutics by 678.9% in the 4th quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company’s stock valued at $104,000 after purchasing an additional 258 shares in the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

UTHR has been the topic of a number of recent research reports. StockNews.com downgraded shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, February 27th. UBS Group lifted their price target on United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. Finally, HC Wainwright restated a “buy” rating and set a $425.00 price objective on shares of United Therapeutics in a research note on Thursday, February 27th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $388.25.

Insider Buying and Selling

In related news, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $360.76, for a total value of $3,607,600.00. Following the transaction, the chief operating officer now owns 2,577 shares in the company, valued at approximately $929,678.52. This represents a 79.51 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Tommy G. Thompson sold 2,500 shares of United Therapeutics stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $318.80, for a total transaction of $797,000.00. Following the sale, the director now owns 8,480 shares of the company’s stock, valued at approximately $2,703,424. The trade was a 22.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 82,755 shares of company stock worth $29,792,021 in the last 90 days. Insiders own 11.90% of the company’s stock.

United Therapeutics Stock Performance

Shares of UTHR stock opened at $308.02 on Friday. United Therapeutics Co. has a fifty-two week low of $221.53 and a fifty-two week high of $417.82. The firm has a market capitalization of $13.83 billion, a price-to-earnings ratio of 13.53, a PEG ratio of 0.97 and a beta of 0.64. The stock’s 50-day simple moving average is $341.10 and its 200-day simple moving average is $355.98.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, topping the consensus estimate of $6.10 by $0.09. The company had revenue of $735.90 million for the quarter, compared to the consensus estimate of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same quarter in the previous year, the firm earned $4.36 EPS. As a group, equities analysts forecast that United Therapeutics Co. will post 24.48 earnings per share for the current year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.